Wuling capsule combined with sertraline in the therapy of anxiety and depression with insomnia in adolescents

BACKGROUND The treatment of adolescent patients with anxiety,depression and insomnia is challenging,and there is no ideal treatment method.AIM To evaluate the clinical efficacy of Wuling capsule combined with sertraline in the treatment of adolescent anxiety,depression and insomnia.METHODS Eighty adolescent patients with anxiety,depression with insomnia who were admitted to our hospital from April 1,2022 to March 30,2024.And the subjects were randomly classified into the control group(n=40)and the observational group(n=40).The control group was treated with a combination of sertraline and placebo.The observation group was treated with Wuling capsule in addition to sertraline.The two groups were cured continuously for 8 weeks.Insomnia severity index(ISI),Hamilton Anxiety Scale(HAMA)and Hamilton Depression Scale(HAMD)were used to evaluate the clinical symptoms before treatment and at 2,4,6 and 8 weeks after treatment.The Treatment Emergent Symptom Scale(TESS)was used to evaluate adverse reactions during treatment.RESULTS There was no obvious difference in HAMD,HAMA and ISI scores between the two groups before treatment(P>0.05).After treatment,the HAMD,HAMA and ISI scores of patients in both groups decreased compared with before treatment,and HAMD,HAMA and ISI scores of patients in the observation group were remarkedly lower than those in the control group at each time point after treatment(P<0.05).Compared with the control group,the TESS score of the study group were sharply lower(t=18.239,P<0.001).CONCLUSION Wuling capsule can further alleviate the insomnia symptoms of adolescents with anxiety and depression,and the efficacy and safety are high.It is recommended to promote the application.

Treatment of functional dyspepsia with sertraline:A double-blind randomized placebo-controlled pilot study

AIM:To evaluate sertraline,a selective serotonin reuptake inhibitor in the treatment of patients with functional dyspepsia.METHODS:Consecutive tertiary hospital patients with a clinical diagnosis of functional dyspepsia(FD) according to the Rome Ⅱ criteria with a Hong Kong dyspepsia index(HKDI) of greater than 16 were recruited.Patients commenced enrolment prior to the inception of the Rome Ⅲ criteria for functional dyspepsia.All patients were ethnic Chinese,had a normal upper endoscopy and were Helicobacter pylori negative prior to enrolment.Study patients were randomized to receive sertraline 50 mg or placebo daily for 8 wk.HKDI symptom scores,quality of life,hospital anxiety and depression(HAD) scale and global symptom relief were evaluated before,during and after treatment.Adverse effects were monitored during and after treatment.RESULTS:A total of 193 patients were randomized in the intention to treat(ITT),and 150 patients were included in the per protocol(PP) analysis.In both the ITT and PP,there was no difference in the primary outcome of global dyspepsia symptoms between the sertraline and placebo groups at week 8.In the ITT analysis,98 and 95 patients were randomized to the sertraline and placebo groups respectively.A total of 43 patients withdrew from the study(22.3%) by week 8,with 23 of the 24 drop-outs in the sertraline group occurring prior to week 4(95.8%).In contrast,in the placebo arm,11 of 19 patients dropped out by week 4(57.9%).Utilizing the last response carried forward to account for the drop-outs,there were no differences between the sertraline and placebo groups at baseline in terms of the HKDI,HKDI 26.08 ± 6.19 vs 26.70 ± 5.89,P = 0.433;and at week 8,HKDI 22.41 ± 6.36 vs 23.25 ± 7.30,P = 0.352 respectively.In the PP analysis,74 and 76 patients were randomized to the sertraline and placebo groups respectively.At baseline,there were no statistically significant differences between the sertraline and placebo groups,HKDI 25.83 ± 6.313 vs 27.19 ± 5.929 respectively,P = 0.233;however by week 8,patients in the sertraline group demonstrated a statistically significant difference in their Hong Kong Dyspepsia Index compared to placebo,HKDI 20.53 ± 6.917 vs 23.34 ± 7.199,P = 0.02,respectively).There was also no statistically significant difference in overall quality of life measures or the HAD scale related to treatment in either the ITT or PP analysis at week 8.CONCLUSION:This pilot study,the first to examine sertraline,a selective serotonin reuptake inhibitor,for the management of FD,did not find that it was superior to placebo.

Comparative study of on-demand and daily use of sertraline in treatment of premature ejaculation:A randomized clinical trial

Objective:The intravaginal ejaculatory latency time(IELT)may increase less in on-demand compared to daily intake,but may fulfill a suitable treatment for specific patients.We decided to compare the efficacy and safety of on-demand and daily use of sertraline in order to find the most effective and least complicated method in treatment of premature ejaculation(PE).Methods:This study was parallel or concurrent control randomized clinical trial.Two hundred and forty patients with PE diagnosed by urologist in the two groups of 120 from July 2017 to February 2019 enrolled in the study.In the first group,it is prescribed 50 mg sertraline each 12 h daily and the second group received 50 mg 4 h before coitus for 4 and 8 weeks.The IELT before treatment and during all coitus after treatment were recorded by the patient’s wife with a stopwatch.Results:Mean IELT before,4 and 8 weeks after treatment in two groups were:On-demand group 101.62±65.44 s,208.75±128.02 s and 265.87±145.70 s;daily use group 102.50-81.22 s,276.87±181.08 s and 353.75±176.45 s,respectively.The ejaculation time increased significantly in both groups(p<0.05).However,increase in ejaculation time in daily use group was significantly higher than the on-demand group in 4 weeks(p=0.036),especially in 8 weeks(p=0.009).The percent of side effects in daily use group(26.7%)was higher than on-demand group(20%)(p<0.05).Drowsiness,diarrhea and vertigo were significantly higher in the daily use than on-demand(p<0.05).Conclusions:On-demand and daily use of sertraline are effective and usually have no serious complications,but the on-demand method is considerably more tolerable.In patients who did not tolerate to daily use of this drug,on-demand could be used as a salvage therapy.

Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model

Bone wound healing is a highly dynamic and precisely controlled process through which damaged bone undergoes repair and complete regeneration. External factors can alter this process, leading to delayed or failed bone wound healing. The findings of recent studies suggest that the use of selective serotonin reuptake inhibitors(SSRIs) can reduce bone mass, precipitate osteoporotic fractures and increase the rate of dental implant failure. With 10% of Americans prescribed antidepressants, the potential of SSRIs to impair bone healing may adversely affect millions of patients’ ability to heal after sustaining trauma. Here, we investigate the effect of the SSRI sertraline on bone healing through pre-treatment with(10 mg·kg-1sertraline in drinking water, n = 26) or without(control, n = 30) SSRI followed by the creation of a 5-mm calvarial defect. Animals were randomized into three surgical groups:(a) empty/sham,(b) implanted with a DermaMatrix scaffold soak-loaded with sterile PBS or(c) DermaMatrix soak-loaded with542.5 ng BMP2. SSRI exposure continued until sacrifice in the exposed groups at 4 weeks after surgery. Sertraline exposure resulted in decreased bone healing with significant decreases in trabecular thickness, trabecular number and osteoclast dysfunction while significantly increasing mature collagen fiber formation. These findings indicate that sertraline exposure can impair bone wound healing through disruption of bone repair and regeneration while promoting or defaulting to scar formation within the defect site.

Single-run reversed-phase HPLC method for determining sertraline content,enantiomeric purity,and related substances in drug substance and finished product

A direct enantio-,diastereo-,and chemo-selective high-performance liquid chromatographic method was developed for determining the content,enantiomeric purity,and related substances of the chiral antidepressant drug sertraline HCl in a single chromatographic run.The separation was achieved on a chiral stationary phase based on amylose tris(3-chloro-5-methylphenylcarbamate)under reversed-phase conditions.The method was optimized by evaluating the influence of the temperature and mobile phase composition on the retention and selectivity.The application of the single-run approach allowed to baseline resolve all investigated species in less than 15 min,without using buffers or tandem-coupled columns.The chromatographic method was validated according to the guidelines of the Official Medicines Control Laboratory and applied to control the content of sertraline HCl and related chiral substances in a generic antidepressant formulation.

Effects of Sertraline on Sperm Motility, Number and Viability and Its Relation to Blood Levels of Testosterone, FSH and LH in Adult Male Mice

The aim of this study was to investigate the effects of Sertraline on gonad-pituitary cycle (Testosterone, FSH and LH) and reproductive cells in adult male Balb/C mice. Adult male Balb/C mice were divided into the following 5 groups: control group with no treatment, sham group which received solvent, and the experimental groups which received one dose of Sertraline (0.0178 mg/kg) in the first group, two doses of Sertraline (0.0356 mg/kg) in the second group, and three doses of Sertraline (0.0534 mg/kg) in the third group. Mice were anaesthetized after 7 weeks. Serum samples were collected and Testosterone, FSH and LH levels of serum were assayed. Vase deferans were analyzed for motility, number and viability of sperms. The results of this study showed that the viability, count and motility of sperms were decreased. Testosterone level of blood was also decreased while FSH was increased. There was no significant change in LH level. It is suggested that Sertraline at higher dose decreases sperm production and has the potential to affect adversely fertility in male mice.

Sertraline Induced Acute Hepatitis: A Case Report

Depression is a common disorder amongst the general population and frequently encountered by most physicians. Selective Serotonin Re-Uptake Inhibitors (SSRI’s) have become the most commonly prescribed antidepressants due to their superiority compared with other antidepressants in the treatment of acute major depression. Although exceedingly rare, hepatotoxicity resulting from sertraline use has been previously reported. In these case reports, the liver injury pattern was predominately hepatocellular. Unlike previous cases, we report the case of a patient presenting with markedly elevated cholestatic enzymes and painless jaundice while taking sertraline for treatment of depression.

Sertraline-induced reproductive toxicity in male rats： evaluation of possible underlying mechanisms

This study was conducted to clarify the toxic effects of sertraline （SRT） on the reproductive system of male rats and to elucidate the underlying mechanisms. Rats were treated orally with SRT at doses of 5, 10, and 20 mg kg-1 for 28 consecutive days. At the end of the treatment period, sperm concentration, sperm motility, and sperm morphology were investigated by computer-assisted sperm analysis system whereas sperm DNA damage was detected by comet assay. The oxidative status of the testes was investigated, and a histopathological examination was conducted. Serum testosterone, follicle-stimulating hormone （FSH）, and luteinizing hormone （LH） levels were measured to determine the effects of SRT on the spermatogenesis process. One-way ANOVA, post-hoc Dunnett＇s T3 test for the sperm comet assay, and post-hoc Tukey＇s test for the others were performed for statistical analysis. The results showed that SRT caused an increase in sperm DNA damage and induced histopathological lesions in all groups treated with SRT. There was abnormal sperm morphology and increased malondialdehyde （MDA） in the 10 mg kg-1 treatment group. More dramatic changes were observed in the 20 mg kg-1 treatment group. Decreased sperm count was accompanied by a significant increase in abnormal sperm morphology, DNA damage, and degeneration in cellular-tubular structures. Serum LH and testosterone levels were elevated in the 20 mg kg-~ treatment group. Decreased glutathione （GSH） and increased MDA were signs of enhanced oxidative stress （OS）. In conclusion, SRT induced testicular toxicity in a dose-dependent manner and OS is suggested as a crucial mechanism.

Evaluation on monoamine neurotransmitters changes in depression rats given with sertraline, meloxicam or/and caffeic acid

Inflammation drives the development of depression and may affect neurotransmitters and thus neurocircuits increase the risk of depression.To investigate the influence of inhibition of inflammatory pathways on the biogenic amine neurotransmitters metabolism in depressive rats,sertraline,and meloxicam,the inhibitors of arachidonic acid-cyclooxygenase-2/lipoxygenase(AA-COX-2/5-LO)pathways,were given to depressive rats.After the development of depression model by chronic unpredictable mild stress(CUMS)for 6 weeks,Successful modeling rats were selected and randomly divided into CUMS group and medication administration group.After given medicine,The biogenic amine neurotransmitters in rat cortex and hippocampus were measured by high-performance liquid chromatography equipped with an electrochemical detector(HPLC-ECD).Compared with the normal group,the concentration of norepinephrine(NE)significantly decreased and the concentrations of Tyrosine(Tyr),Tryptophan(Trp),3,4-dihydroxyphenyl acetic acid(DOPAC),3-methoxy-4-hydroxyphenylglycol(MHPG),homovanillic acid(HVA)and 5-hydroxyindoleacetic acid(5-HIAA)significantly increased in the CUMS group.Sertraline significantly inhibited the elevation of 5-HIAA.Meloxicam inhibited the decrease of NE level in CUMS-induced rat and the increase of Trp,MHPG,and 5-HIAA level in a dose-dependent manner.Caffeic acid inhibited the decrease of NE and the increase of Trp and MHPG in a dose-dependent manner.The inhibition of AA-COX-2/5-LO pathways can improve the behaviors of depression rats and suppress CUMSinduced changes in biogenic amines.Compared with the single-dose lipoxygenase(5-LO)or Cyclooxygenase-2(COX-2)inhibitor,the combination treatment with meloxicam 1 mg/kg and caffeic acid 10 mg/kg have no significant improvement in CUMS-induced depression behavior and the level of cortical monoamine neurotransmitters and their metabolites.

Sertraline联合Aripiprazole可显著上调大鼠脑部的CREB和BDNF水平

为了探讨SSRI联合抗精神病药物对脑源性神经营养因子(brain derived neurotrophic factor, BDNF)-cAMP反应元件结合蛋白(cAMP response element binding, CREB)信号通路的影响,本研究将SD大鼠随机分成5组,每组10只,各组大鼠分别腹腔注射阿立哌唑(5 mg·kg-1·d-1,阿立哌唑组)、舍曲林(5 mg·kg-1·d-1,舍曲林组)、阿立哌唑+舍曲林(5 mg·kg-1·d-1+5 mg·kg-1·d-1,联合组),奥氮平(5 mg·kg-1·d-1,奥氮平组)和不含药物的溶液(对照组),连续注射3周。研究显示,联合组显著增加大鼠的海马区BDNF平均荧光强度和蛋白水平,但在其他组未观察到对BDNF水平的影响。另外,不同组处理对额皮质中的BDNF水平没有影响。联合组显著增加了海马和额皮质的CREB磷酸化,而单独药物处理对CREB磷酸化无影响。联合组显著增加大鼠的海马和额皮质中CREB和TrkB (BDNF受体)的mRNA表达水平,以及AKT的磷酸化。综上所述,舍曲林联合抗精神病药(阿立哌唑)可显著上调大鼠脑部的CREB和BDNF水平,并且参与调节BDNF-CREB-AKT信号通路及相关分子。

舍曲林与认知行为疗法联合治疗青少年抑郁症的效果

目的 探讨分析在青少年抑郁症中联合应用舍曲林与认知行为疗法干预对临床疗效的影响。方法 抽取2020年7月至2023年3月泉州市第三医院接诊的青少年抑郁症患者96例为研究对象,根据就诊挂号顺序将患者分为对照组(单数)和观察组(双数),各48例,给予对照组单独舍曲林干预,给予观察组舍曲林与认知行为疗法联合干预。对两组干预前后的汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、自杀态度量表(QSA)评分进行比较,同时统计两组临床治疗总有效率。结果 干预4周、8周后,两组HAMD、HAMA评分均较干预前降低,且观察组降低幅度比对照组大(P <0.05);干预8周后,两组QSA各维度(对自杀行为性质认知、对自杀者的态度、对自杀家属的态度、对安乐死的态度)评分均较干预前升高,观察组升高幅度比对照组大(P <0.05);观察组临床治疗总有效率95.83%高于对照组81.25%(χ^(2)=5.031,P=5.031)。结论 青少年抑郁症患者中联合应用舍曲林与认知行为疗法干预能够获得理想的干预效果,可减轻其抑郁、焦虑症状程度,扭转其自杀意识。

舍曲林联合理性情绪疗法对首发青少年抑郁症患者的临床观察

目的:探讨舍曲林联合理性情绪疗法对首发青少年抑郁症患者的临床疗效和安全性。方法:纳入2020年4月至2022年4月于武汉市第一医院神经内科睡眠与心理门诊就诊的首发青少年抑郁症患者90例,采用随机数字表法分为两组,研究组和对照组各45例,研究组采用舍曲林联合理性情绪疗法,对照组给予舍曲林治疗。于治疗前及治疗第4、8周末,采用汉密尔顿抑郁量表(HAMD)、症状自评量表(SCL-90)评估情绪状态,采用治疗副反应量表(TESS)评估药物的安全性。结果:治疗4周、治疗8周,两组的HAMD总分及焦虑/躯体化、认知障碍、阻滞、全身症状等因子分均较治疗前下降(P均<0.05),且研究组的HAMD总分、认知障碍、阻滞均低于对照组(P均<0.05),重复测量方差分析显示治疗8周的HAMD总粗分及认知障碍、睡眠障碍等因子分均低于治疗4周(P均<0.05)。研究组治疗4周、治疗8周的SCL-90总分均低于治疗前,且研究组低于对照组(P<0.05)。治疗后两组TESS评分对比差异无统计学意义(P>0.05),不良反应主要为恶心、头晕、嗜睡。结论:舍曲林联合理性情绪疗法可有效改善青少年抑郁症状,优于单一药物治疗,且安全性理想,值得临床推广应用。

盐酸舍曲林和草酸艾司西酞普兰用于抑郁症治疗的安全性比较:基于FAERS数据库不良事件分析

目的通过对美国FDA不良事件报告系统(FAERS)数据库的数据挖掘,探讨盐酸舍曲林和草酸艾司西酞普兰的安全性差异。方法采用报告比值比(ROR)法和比例报告比值比(PRR)法,对FAERS数据库中2011年第1季度至2023年第2季度报告的盐酸舍曲林和草酸艾司西酞普兰的不良事件进行数据挖掘。结果女性发生不良事件的比例高于男性(男女比例约为1∶2)。盐酸舍曲林和草酸艾司西酞普兰均在18~64岁年龄组中的报告频率更高。累及系统器官分布方面,盐酸舍曲林组和草酸艾司西酞普兰组相似,但在生殖系统及乳腺疾病毒性方面存在差异,盐酸舍曲林的生殖器感觉减退信号更多,草酸艾司西酞普兰则更影响溢乳。在检测到的前10个报告信号中,药物相互作用、药物无效、恶心、头晕、头痛、焦虑的信号在盐酸舍曲林和草酸艾司西酞普兰中均有生成,盐酸舍曲林组中发生自杀意念、药物相互作用、震颤、焦虑等不良事件的可能性更大,草酸艾司西酞普兰组中更可能发生产品替换问题、妊娠期胎儿暴露、药物相互作用,提示二者的高频不良事件之间存在差异。结论盐酸舍曲林和草酸艾司西酞普兰具有相同的部分高频不良事件、相似的全身器官分布和相似的总体安全性,但在精神病类和各类检查方面存在差异,草酸艾司西酞普兰出现心电图QT间期延长不良信号强,用药后应定期复查心电图,减少晕厥、心脏骤停或死亡的风险。盐酸舍曲林出现自杀想法的信号强度高,应重视患者在治疗期间持续出现自杀想法。

舍曲林联合右佐匹克隆治疗脑卒中后抑郁的临床效果及对睡眠质量的影响

目的分析脑卒中后抑郁患者以舍曲林联合右佐匹克隆方式展开临床治疗的效果,并探究对患者睡眠质量的影响。方法选取2020年10月—2022年12月赤峰市医院神经内科收治的72例脑卒中后抑郁患者作为研究对象,以单盲分组方法实施组别划分,分为参照组(n=36)与研究组(n=36),参照组以舍曲林为患者实施药物治疗,研究组以舍曲林联合右佐匹克隆方式为患者实施药物治疗,对两组患者临床治疗效果进行比较。结果研究组的总有效率(94.44%)高于参照组,差异有统计学意义(χ^(2)=6.400,P<0.05);治疗后,研究组的血清中枢神经特异蛋白显著低于参照组,且脑源性神经营养因子明显高于参照组,差异有统计学意义(P均<0.05);治疗后,研究组的神经功能缺损评估量表评分、匹兹堡睡眠质量指数量表评分、汉密顿抑郁量表评分、汉密尔顿焦虑量表评分均低于参照组,差异有统计学意义(P均<0.05);研究组的超敏C反应蛋白低于参照组,且血管内皮生长因子高于参照组,差异有统计学意义(P均<0.05)。结论脑卒中后抑郁患者以舍曲林联合右佐匹克隆方式实施药物治疗,可改善患者神经功能与睡眠质量,有助于患者临床治疗效果的提升,对缓解患者抑郁症状具有积极意义。

五行针灸联合舍曲林治疗抑郁症临床研究

目的 观察盐酸舍曲林片联合五行针灸治疗抑郁症的有效性与安全性。方法 纳入60例抑郁症患者,随机分为治疗组和对照组各30例。2组均口服盐酸舍曲林片,治疗组加用五行针灸治疗,共治疗70 d。分别在治疗前后应用汉密尔顿抑郁量表(HAMD)、比较5-羟色胺水平来评估受试者的抑郁状态。结果 治疗后,2组的HAMD评分、5-羟色胺水平均较治疗前明显改善(P<0.05),且治疗组优于对照组(P<0.05)。结论 舍曲林联合五行针灸治疗能够有效的降低抑郁症患者量表评分,提高5-羟色胺水平,治疗效果显著。

九味镇心颗粒结合舍曲林对伴非自杀性自伤青少年抑郁症患者抑郁情绪、自伤水平及冲动行为的影响

目的 观察九味镇心颗粒结合舍曲林对伴非自杀性自伤青少年抑郁症患者抑郁情绪、自伤水平及冲动行为的影响。方法 前瞻性选取2022年1月至2023年2月潍坊市精神卫生中心收治的65例伴非自杀性自伤青少年抑郁症患者,按照奇偶数分组法分为舍曲林组(n=32)和联合组(n=33)。舍曲林组给予舍曲林治疗,联合组给予九味镇心颗粒结合舍曲林治疗。两组疗程均为8周。评估并比较两组治疗前和治疗8周后的自我伤害行为筛选量表评分、情绪调节困难量表(DERS)评分、汉密尔顿抑郁量表(HAMD)评分、抑郁自评量表(SDS)评分、Barratt冲动量表(BIS-II)评分差异,检测两组治疗前和治疗8周后的神经递质(5-羟色胺、P物质、皮质醇)水平,记录并比较两组不良反应。结果 治疗8周后,联合组的忧郁孤独、自残自杀、退缩与自我批评及总分分别为(5.82±1.47)、(2.56±0.78)、(2.95±0.95)、(15.57±3.11)分,均低于舍曲林组[(7.95±1.89)、(4.25±1.06)、(3.57±1.24)、(20.03±3.56)分],差异均有统计学意义(P<0.05),而攻击违纪、行为改变评分与舍曲林组比较,差异均无统计学意义(P>0.05)。治疗8周后,联合组的HAMD评分、SDS评分、DERS评分、BIS-Ⅱ评分分别为(11.74±3.04)、(28.78±4.12)、(105.85±15.43)、(24.17±3.86)分,均低于舍曲林组[(15.45±3.56)、(39.45±4.56)、(114.56±14.62)、(27.23±4.11)分],差异均有统计学意义(P<0.05)。治疗8周后,联合组5-羟色胺水平为(89.52±5.04)ng/mL,高于舍曲林组[(43.69±4.75)ng/mL],P物质、皮质醇水平分别为(37.95±7.44)ng/L、(72.25±18.89)μg/L,均低于舍曲林组[(46.54±8.12)ng/L、(95.85±21.04)μg/L],差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 九味镇心颗粒结合舍曲林可减轻伴非自杀性自伤青少年抑郁症患者抑郁情绪,减轻自伤和冲动行为,可能与调节神经递质有关。

阴茎交感神经皮肤反应评估养阴清热中药治疗阴虚火旺型早泄患者疗效的可行性研究

目的:探讨养阴清热中药(加减知柏地黄汤)治疗阴虚火旺型早泄患者的临床疗效及阴茎交感神经皮肤反应(PSSR)评估在其中的应用价值。方法:选取2022年1月—2023年12月浙江大学医学院附属第二医院收治的阴虚火旺型原发性早泄(PPE)患者共96例,随机将其分为治疗组(养阴清热中药)与对照组(盐酸舍曲林片50 mg)两组,治疗周期均为8周。观察两组患者治疗前后阴道内潜伏时间(IELT)、早泄诊断量表(PEDT)、PSSR潜伏期和波幅、国际勃起功能指数-5(IIEF-5)的变化。结果:治疗前和治疗后,两组IELT、PEDT、PSSR波幅、PSSR潜伏期比较,差异无统计学意义(P>0.05);治疗后,两组IELT、PSSR潜伏期均高于治疗前,PEDT、PSSR波幅低于治疗前,差异有统计学意义(P<0.05)。两组治疗前后IIEF-5相比,差异均无统计学意义(P>0.05)。结论:养阴清热中药治疗阴虚火旺型PPE的疗效肯定,PSSR潜伏期是其临床疗效的一种较为客观的评价指标。

固定化c-ω-转氨酶催化合成(4S)-四氢萘酮

以T4噬菌体衣壳为载体,探索了海绵假弧菌-ω-转氨酶(P-ω-TA)的自组装固定化,以将P-ω-TA与T4噬菌体非必需小外壳蛋白(Soc)融合的方式实现了P-ω-TA在T4噬菌体衣壳上的亲和固定及较高的位点结合数。对固定化P-ω-TA的适应性、回收性能、(S)-型异构体选择性拆分及(1S,4S)-去甲基舍曲林的催化能力进行了测试。结果表明,固定化的P-ω-TA保持了完整的活性及适应性,可通过离心操作轻松地回收,并进行重复使用。在5次回收和重复使用过程中,每次酶活回收率均>91%,经5次催化,最终酶活保持率约为84%。固定化P-ω-TA保持了在底物手性中心处的(S)-型异构体选择性拆分以及对(1S,4S)-去甲基舍曲林的催化能力。

舍曲林片联合相对卧床式森田疗法在伴非自杀性自伤青少年抑郁症中的应用效果

目的探讨舍曲林片联合相对卧床式森田疗法在伴非自杀性自伤(NSSI)青少年抑郁症中的应用效果。方法选取2021年1月至2022年12月赣州市第三人民医院精神科收治的60例伴NSSI的青少年抑郁症患者作为研究对象,按照随机数字表法将其分为对照组(30例)和研究组(30例)。对照组患者采用单一的舍曲林片治疗,研究组患者采用舍曲林片与相对卧床式森田疗法联合治疗。比较两组治疗前及治疗2、4、6周后的渥太华自伤量表(OSI)、汉密尔顿抑郁量表(HAMD)和生活质量简表(SF-36)评分。结果研究组治疗2、4、6周后的OSI评分均低于对照组,差异有统计学意义(P<0.05);研究组治疗2、4、6周后的HAMD评分均低于对照组,差异有统计学意义(P<0.05);研究组治疗6周后的SF-36评分高于对照组,差异有统计学意义(P<0.05)。结论伴NSSI青少年抑郁症患者采用舍曲林片与相对卧床式森田疗法联合治疗的效果较显著,不仅能有效减少其自伤行为的发生,还能减轻其抑郁症状,提高其生活质量,临床可进一步推广。